Starling Oncology launches Nexus oncology technology platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
August 17, 2026 8:00 AM EDTCompanys proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow
CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology Inc. (NASDAQ: STLN), (STLN or the Company), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer cares persistent challenges: NCCN compliance by the medical community and a fragmented and administratively burdensome prior authorization process for providers.
Oncology treatment decisions are complex and time-sensitive for patients, yet prior... More



